Business Context and Reporting Period
Company: Klotho Neurosciences, Inc. (Note: Input metadata referenced "Greenland Mines Ltd," but the filing text identifies the registrant as Klotho Neurosciences, Inc.)
Filing Type: Form 8-K (Current Report)
Date: January 23, 2025
Context: The Company, an emerging growth company, entered into a Securities Purchase Agreement with an institutional investor to raise capital through senior convertible promissory notes and warrants.
Key Financial Metrics and Transaction Details
- Total Capital Raised (Committed): $2,000,000 aggregate purchase price.
- Initial Closing (Jan 23, 2025): $1,000,000 received for the First Note and First Warrant.
- Second Tranche (Contingent): $1,000,000 to be received upon SEC registration statement effectiveness.
- Debt Instrument: Two senior convertible promissory notes with an aggregate principal amount of $2,173,914.
- Interest Rate: 7% per annum.
- Original Issue Discount (OID): 8%.
- Conversion Price: $0.25 per share of Common Stock.
- Warrants: Rights to purchase up to 4,000,000 shares at an exercise price of $0.50 per share; expire in five years.
- Liquidity Impact: Immediate cash inflow of $1,000,000; potential additional $1,000,000 pending regulatory approval.
Material Changes and Agreements
The filing reports the creation of a direct financial obligation and unregistered sales of equity securities. Key terms include:
- Conversion Restrictions: Conversions are limited if the investor would own more than 4.99% (or up to 9.99% under specific terms) of outstanding shares. Conversions also require Nasdaq rule compliance.
- Stockholder Approval: The Company must hold a stockholder meeting within 90 days to approve issuances exceeding 19.99% of outstanding shares. If not obtained, meetings must be held every three months thereafter.
- Voting Agreement: Certain officers, directors, and shareholders agreed to vote in favor of the issuance of shares exceeding 20% of outstanding shares to the investor.
- Registration Rights: The Company must file a registration statement within 15 days of the closing date to register shares issuable upon conversion or exercise.
Outlook, Risks, and Contingencies
- Contingent Funding: The second $1,000,000 tranche is contingent upon the SEC declaring the registration statement effective.
- Dilution Risk: Full conversion and exercise could result in the issuance of a significant number of shares, subject to the 19.99% stockholder approval threshold.
- Default Provisions: Events of default (e.g., bankruptcy, insolvency) allow the investor to demand immediate repayment of all outstanding principal.
- Regulatory Compliance: The transaction is subject to Nasdaq listing rules and SEC registration requirements.
Investor Verification Checklist
- Verify the current number of outstanding shares to calculate the exact dilution impact of the 4,000,000 warrant shares and potential note conversions.
- Confirm the status of the registration statement filing required within 15 days of January 23, 2025.
- Review the Company's current cash position to assess the immediate impact of the $1,000,000 initial closing.
- Monitor the schedule for the upcoming stockholder meeting required within 90 days for approval of issuances exceeding 19.99%.
- Check for any existing indebtedness that ranks equal to or senior to these new notes.